Skip to main content
SpringerLink
Log in

Chemoprevention of Cancer by NSAIDs and Selective COX-2 Blockade

  • Chapter
COX-2 Blockade in Cancer Prevention and Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 130 Accesses

Abstract

Two components of arachidonic acid (AA) metabolism are strongly associated with carcinogenesis—the leukotriene and prostaglandin (PG) synthesis pathways. Both pathways are inhibited by antioxidants and anti-inflammatory agents. Blocking the PG synthesis pathway by inhibiting the activity of the cyclooxygenase (COX) component of prostaglandin H (PGH) synthase using nonsteroidal anti-inflammatory drugs (NSAIDs), and particularly COX-2 selective inhibitors, is a prominent and highly promising strategy for cancer chemoprevention (1–6). The rationale for suppressing COX activity or expression in chemoprevention is strengthened by the observation of COX elevation in many cancers and precancerous lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 1073–1077.

    Article  PubMed  CAS  Google Scholar 

  2. Singh DK, Lippman SM. Cancer chemoprevention. Part 2: hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Oncology (Huntingt) 1998; 12:1787–1800; discussion 1802, 1805.

    Google Scholar 

  3. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). JNatl Cancerinst 1998; 90: 1529 1536.

    Google Scholar 

  4. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). JNatl Cancerinst 1998; 90: 1609 1620.

    Google Scholar 

  5. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999; 8: 1623–1638.

    Article  PubMed  CAS  Google Scholar 

  6. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 278: 199–334.

    Google Scholar 

  7. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 192; 52:55755589.

    Google Scholar 

  8. Zenser TV, Davis BB. Arachidonic acid metabolism. In: Steele VE, Stoner GD, Boone CW, Kelloff GJ, eds. Cellular and Molecular Targets for Chemoprevention. CRC, Boca Raton, FL, 1992, pp. 225243.

    Google Scholar 

  9. Kelloff GJ, Boone CW, Steele VE, Fay JR, Sigman CC. (1995). Inhibition of chemical carcinogenesis. In: Arcos J, Argus M, Woo Y, eds. Chemical Induction of Cancer: Modulation and Combination Effects. Birkhäuser, Boston, MA, 1995, pp. 73–122.

    Chapter  Google Scholar 

  10. Marnett LJ, Reed GA, Dennison DJ. Prostaglandin synthetase dependent activation of 7,8-dihydro7,8-dihydroxybenzo (a) pyrene to mutagenic derivatives. Biochem Biophys Res Commun 1978; 82: 210–216.

    Article  PubMed  CAS  Google Scholar 

  11. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681–686.

    Article  PubMed  CAS  Google Scholar 

  12. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989; 165: 888–894.

    Article  PubMed  CAS  Google Scholar 

  13. Fletcher BS, Kujubu DA, Perrin DM, Herschman, HR. Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS 10-encoded protein is a functional prostaglandin GM synthase. J Biol Chem 1992; 276: 4338–4344.

    Google Scholar 

  14. Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5’-flanking regulatory sequences. Arch Biochem Biophys 1992; 293: 391–400.

    Article  PubMed  CAS  Google Scholar 

  15. Isakson P, Seibert K, Masferrer J, Salvemini D, Lee L, Needleman P Discovery of a better aspirin. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 49–54.

    PubMed  CAS  Google Scholar 

  16. Miller DB, Munster D, Wasvary JS, Simke JP, Peppard JV, Bowen BJ, et al. The heterologous expression and characterization of human prostaglandin GM synthase-2 (COX-2). Biochem Biophys Res Comm 1994; 201: 356–362.

    Article  PubMed  CAS  Google Scholar 

  17. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263, F181 - F191.

    PubMed  CAS  Google Scholar 

  18. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cylooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610–6614.

    PubMed  CAS  Google Scholar 

  19. Meade EA, Smith WL, DeWitt DL. Expression of the murine prostaglandin (PGH) synthase-1 and PGH synthase-2 isozymes in cos-1 cells. J Lipid Med 1993; 6: 119–129.

    CAS  Google Scholar 

  20. Klein T, Nüsing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994; 48: 1605–1610.

    Article  PubMed  CAS  Google Scholar 

  21. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90:11, 693–11, 697.

    Google Scholar 

  22. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991; 60, 281–319.

    Article  PubMed  CAS  Google Scholar 

  23. Ryseck R, Raynoschek C, MacDonald-Bravo H, Dorfman K, Bravo R. Identification of an immediate early gene, PGHS-b, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differentiation 1992; 3: 443–450.

    PubMed  CAS  Google Scholar 

  24. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2. Ann NYAcad Sci 1994; 14: 136–142.

    Article  Google Scholar 

  25. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566–4569.

    PubMed  CAS  Google Scholar 

  26. Ding X-Z, Tong W-G, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000; 20: 2625–2632.

    PubMed  CAS  Google Scholar 

  27. Baud L, Perez J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138: 190–1195.

    Google Scholar 

  28. Versteeg HH, van Bergen en Henegouwen PMP, van Deventer SJH, Peppelenbosch MP. Cyclooxygenase-dependent signalling: molecular events and consequences. FEBS Lett 1999; 445: 1–5.

    Article  PubMed  CAS  Google Scholar 

  29. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55; 1811–1816.

    PubMed  CAS  Google Scholar 

  30. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpres sing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501.

    Article  PubMed  CAS  Google Scholar 

  31. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis andBcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362–366.

    PubMed  CAS  Google Scholar 

  32. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88: 600–604.

    Article  PubMed  CAS  Google Scholar 

  33. Smith M-L, Hawcroft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 1998; 36: 664–674.

    Article  Google Scholar 

  34. Sawaoka H, Kawano S, Tsuji S, Tsuji M, Gunawan ES, Takei Y, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G1061 - G1067.

    PubMed  CAS  Google Scholar 

  35. Hsu A-L, Ching T-T, Wang D-S, Song X, Rangnekar VM, Chen C-S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of bcl-2. J Biol Chem 2000; 275:11,397–11,403.

    Google Scholar 

  36. Liu X-H, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 245–249.

    Google Scholar 

  37. Zimmermann KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE, Schror K.Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198–204.

    PubMed  CAS  Google Scholar 

  38. Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 2000; 26: 731–742.

    Article  PubMed  Google Scholar 

  39. Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 1999; 90: 1152–1162.

    Article  PubMed  CAS  Google Scholar 

  40. He T-C, Chan TA, Vogelstein B, Kinzler, KW. PPARS is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335–345.

    Article  PubMed  CAS  Google Scholar 

  41. Folkman J. What is the evidence that tumors are angiogenesis dependent? JNatl Cancerinst 1990; 82: 4–6.

    Article  CAS  Google Scholar 

  42. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–716.

    Article  PubMed  CAS  Google Scholar 

  43. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 over-expression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83: 324–328.

    Article  PubMed  CAS  Google Scholar 

  44. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 135–138.

    PubMed  CAS  Google Scholar 

  45. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–3340.

    Article  PubMed  CAS  Google Scholar 

  46. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woemer BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–1311.

    PubMed  CAS  Google Scholar 

  47. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors: a new class of antiangiogenic agents. Ann NY Acad Sci 1999; 889: 84–86.

    Article  PubMed  CAS  Google Scholar 

  48. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress anigogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469–1477.

    PubMed  CAS  Google Scholar 

  49. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130: 641–649.

    Article  PubMed  CAS  Google Scholar 

  50. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh LI, et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418–1423.

    Article  PubMed  CAS  Google Scholar 

  51. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome proliferator-activated receptor-y(PPAR-’y), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671–5673.

    PubMed  CAS  Google Scholar 

  52. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor y, retinoids, and prevention of preneoplastic mammary lesions. JNatl Cancerinst 2000; 92: 418–423.

    Article  CAS  Google Scholar 

  53. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor 130). Mol Cell Biol 2000; 20: 5119–5128.

    Article  PubMed  CAS  Google Scholar 

  54. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76: 655–663.

    PubMed  CAS  Google Scholar 

  55. McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 1990; 50: 8023–8027.

    PubMed  CAS  Google Scholar 

  56. Balch CM, Dougherty PA, Cloud GA, Tilden, AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 1984; 95: 71–77.

    PubMed  CAS  Google Scholar 

  57. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation Prostaglandins Other Lipid Mediat 2000; 62: 367–384.

    Article  PubMed  CAS  Google Scholar 

  58. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275:33, 951–33, 956.

    Google Scholar 

  59. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997; 94: 657–662.

    Article  PubMed  CAS  Google Scholar 

  60. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994; 62: 175–191.

    Article  PubMed  CAS  Google Scholar 

  61. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflanunatory drug, with D,L-a-difluo-ro-methylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50: 2562–2568.

    PubMed  CAS  Google Scholar 

  62. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6: 1024–1028.

    Article  PubMed  CAS  Google Scholar 

  63. Martin MJ, Jimenez MD, Motilva V. New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Des 20011; 7: 881–908.

    Google Scholar 

  64. Solaraze (diclofenac sodium) Gel USPI, 2000.

    Google Scholar 

  65. Thompson WJ, Pamukcu R, Liu L, Li H, Ahnen D, Speri G, et al. Exisulind (Prevatac) induced apoptosis in cultured colonic tumor cells involves inhibition of cyclic GMP (cG) phosphodiesterase (PDE). Cancer Res 2000; 60: 3338–3342.

    PubMed  CAS  Google Scholar 

  66. Wechter WJ, Murray ED Jr, Kantoci D, Quiggle DD, Leipold DD, Gibson KM, et al. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci 2000; 66: 745753.

    Google Scholar 

  67. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000; 60: 2203–2208.

    PubMed  CAS  Google Scholar 

  68. Karim MM, Hayashi Y, Inoue M, Imai Y, Ito H, Yamamoto M. Cox-2 expression in retinoblastoma. Am J Ophthalmol 2000; 129: 398–401.

    Article  PubMed  CAS  Google Scholar 

  69. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol (Berl) 1999; 98: 240–244.

    Article  CAS  Google Scholar 

  70. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229–1238.

    PubMed  CAS  Google Scholar 

  71. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is over-expressed in human cervical cancer. Clin Cancer Res 2001; 7: 429–434.

    PubMed  CAS  Google Scholar 

  72. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545–553.

    Article  PubMed  CAS  Google Scholar 

  73. Fujita M, Fukui H, Kusaka T, Morita K, Fujii S, Ueda Y, et al. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 2000; 15: 1277–1281.

    PubMed  CAS  Google Scholar 

  74. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470–475.

    Article  PubMed  CAS  Google Scholar 

  75. Soslow RA, Dannenberg Ai, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637–2645.

    Article  PubMed  CAS  Google Scholar 

  76. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett’s esophagus. Dig Dis Sci 2001; 46: 785–789.

    Article  PubMed  CAS  Google Scholar 

  77. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990–996.

    PubMed  CAS  Google Scholar 

  78. Morson BC. Markers for increased risk of colorectal cancer. In: Sherlock P, Morson BC, Barbara L, Veronesi U, eds. Precancerous Lesions of the Gastrointestinal Tract. Raven, New York, 1983, pp. 255–259.

    Google Scholar 

  79. Hamilton SR. The adenoma-adenocarcinoma sequence in the large bowel: variations on a theme. J Cell Biochem 1992; (Suppl)16G:41–46.

    Google Scholar 

  80. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.

    Article  PubMed  CAS  Google Scholar 

  81. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335–351.

    Article  PubMed  CAS  Google Scholar 

  82. Winawer SJ, O’Brien MJ, Waye JD, Kronborg O, Bond J, Fruhmorgen P, et al. Risk and surveillance of individuals with colorectal polyps. Bull WHO 1990; 68: 789–795.

    PubMed  CAS  Google Scholar 

  83. Winawer SJ, Zauber AG, O’Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. NEngl JMed 1993; 328: 901–906.

    Article  CAS  Google Scholar 

  84. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277–1284.

    Article  PubMed  CAS  Google Scholar 

  85. Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 1999;(Supp1)86:2551–2563.

    Google Scholar 

  86. Greenberg ER, Baron JA. Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents In: Stewart BW, McGregor D, Kleihues P, eds. Principles of Chemoprevention, IARC Scientific Publication No 139, Lyon: International Agency for Research on Cancer, 1996, pp. 91–98.

    Google Scholar 

  87. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1–20.

    Article  PubMed  CAS  Google Scholar 

  88. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl JMed 1993; 328: 1313 1316.

    Google Scholar 

  89. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999; 470: 45–53.

    Article  PubMed  CAS  Google Scholar 

  90. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. NEngl JMed 2000; 242: 1946–1952.

    Article  Google Scholar 

  91. PDQ 2001 Randomized Study of Celecoxib for Prevention of New Sporadic Adenomatous Colorectal Polyps in Patients Who Have Undergone Polypectomy NCI Protocol Number: NCI-P00–0141.

    Google Scholar 

  92. PDQ 2001 Phase IIB Randomized Study of Eflornithine (DFMO) and Sulindac Versus Placebo in the Prevention of Colorectal Carcinoma in Patients With Previously Resected Colorectal Adenoma NCI Protocol Number: NCI-P00–0150.

    Google Scholar 

  93. Oshima M, Murai(Hata) N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apc d716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor Cancer Res 2001; 61: 1733–1740.

    PubMed  CAS  Google Scholar 

  94. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992; 6: 1–30.

    CAS  Google Scholar 

  95. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998; 58: 3028–3031.

    PubMed  CAS  Google Scholar 

  96. Castelao JE, Yuan J-M, Gago-Dominguez M, Yu MC, Ross RK. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82: 1364–1369.

    Article  PubMed  CAS  Google Scholar 

  97. Knapp DW, Richardson RC, Bottoms GD, Teclaw R, Chan TCK. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992; 29: 214–218.

    Article  PubMed  CAS  Google Scholar 

  98. Shimamura T, Takahashi S. Reduced proliferation of cultured bladder cancer cells by indomethacin. N Engl J Med 1994; 91: 532–535.

    CAS  Google Scholar 

  99. Cook GP, Hampton JA. Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Anticancer Res 1997; 17: 365–368.

    PubMed  CAS  Google Scholar 

  100. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001; 61: 3961–3968.

    PubMed  CAS  Google Scholar 

  101. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits N-butylN-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599–5602.

    PubMed  CAS  Google Scholar 

  102. PDQ 2001 Phase IIB/III Randomized Chemoprevention Study of Celecoxib in Patients With Superficial Transitional Cell Carcinoma of the Bladder At High Risk For Recurrence NCI Protocol Number: NCI-P00–0165.

    Google Scholar 

  103. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2–8.

    PubMed  CAS  Google Scholar 

  104. Kim R, Weissfeld JL, Reynolds JC, Kuller LH. Etiology of Barrett’s metaplasia and esophageal carcinoma. Cancer Epidemiol Biomarkers Prey 1997; 6: 369–377.

    CAS  Google Scholar 

  105. Heath EI, Limburg PJ, Hawk ET, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Huntingt) 2000; 14:507–514; discussion 518–520, 522, 523.

    Google Scholar 

  106. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am J Gastroenterol 1999; 94: 86–91.

    Article  PubMed  CAS  Google Scholar 

  107. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929–2934.

    PubMed  CAS  Google Scholar 

  108. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prey 1998; 7: 97–102.

    CAS  Google Scholar 

  109. FunkhouserEM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116 1119.

    Google Scholar 

  110. Li M, Lotan R, Levin B., Tahara E, Lippman SM, Xu X-C. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prey 2000; 9: 545–549.

    CAS  Google Scholar 

  111. PDQ 2001 Phase II Randomized Chemoprevention Study of Celecoxib in Patients With Barrett’s Esophagus NCI Protocol Number: NCI-P00–0145.

    Google Scholar 

  112. Tan W, Song N, Wang G-Q, Liu Q, Tang H-J, Kadlubar FF, Lin D-X. Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases Ml, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarkers Prey 2000; 9: 551–556.

    CAS  Google Scholar 

  113. Morita M, Kuwano H, Yasuda M, Watanabe M, Ohno S, Saito T, et al. The multicentric occurrence of squamous epithelial dysplasia and squamous cell carcinoma in the esophagus. Cancer 1994; 74: 2889–2895.

    Article  PubMed  CAS  Google Scholar 

  114. Nagamatsu M, Mori M, Kuwano H, Sugimachi K, Akiyoshi T. Serial histologic investigation of squamous epithelial dysplasia associated with carcinoma of the esophagus. Cancer 1992; 69: 1094–1098.

    Article  PubMed  CAS  Google Scholar 

  115. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483–1492.

    Article  PubMed  CAS  Google Scholar 

  116. Marks R. An overview of skin cancers: incidence and causation. Cancer 1995; 75: 607–612.

    Article  PubMed  CAS  Google Scholar 

  117. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723–729.

    Article  PubMed  CAS  Google Scholar 

  118. Grewe M, Trefzer U, Ballhorn A, Gyufko K, Henninger H, Krutmann J. Analysis of the mechanism of ultraviolet (UV) B radiation-induced prostaglandin E2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol 1993; 101: 528–531.

    Article  PubMed  CAS  Google Scholar 

  119. Fischer SM, Lo H-H, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25: 231–240.

    Article  PubMed  CAS  Google Scholar 

  120. Pentland AP, Schoggins JW, Scott GA, Khan KNM, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20: 1939–1944.

    Article  PubMed  CAS  Google Scholar 

  121. PDQ 2001 Phase II/III Randomized Study of Celecoxib in Patients With Actinic Keratoses NCI Protocol Number: NCI-P00–0161.

    Google Scholar 

  122. PDQ 2001 Phase II Randomized Study of Celecoxib for Chemoprevention of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome NCI Protocol Number: NCI-P01–0190.

    Google Scholar 

  123. PDQ 2001 Phase II Randomized Study of Celecoxib as a Chemopreventive Agent Inhibiting UV-Induced Erythema and Biomarkers of Cutaneous Carcinogenesis in Participants With Fitzpatrick Type I-IV Skin NCI Protocol Number: NCI-P01–0191.

    Google Scholar 

  124. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138–146.

    Article  PubMed  CAS  Google Scholar 

  125. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996; 7: 203–205.

    Article  PubMed  CAS  Google Scholar 

  126. Harris RE, Namboodiri K, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prey Med 1995; 24: 119–120.

    Article  CAS  Google Scholar 

  127. Harris RE, Namboodiri KK, Farrar WB. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1995; 2: 591–592.

    PubMed  CAS  Google Scholar 

  128. Coogan PF, Rao RS, Rosenberg L, Palmer JR, Strom BL, Zauber AG, et al. The relationship of non-steroidal anti-inflammatory drug use to the risk of breast cancer. Prey Med 1999; 29: 72–76.

    Article  CAS  Google Scholar 

  129. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 1061–1070.

    PubMed  CAS  Google Scholar 

  130. Bennett A, McDonald AM, Stamford IF, Charlier EM, Simpson JS, Zebro T. Prostaglandin and breast cancer. Lancet 1977; 2: 624–626.

    Article  PubMed  CAS  Google Scholar 

  131. Powles TJ, Dowsett M, Easty GC, Easty DM, Neville AM. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet 1976; 1: 608–610.

    Article  PubMed  CAS  Google Scholar 

  132. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455–460.

    Article  PubMed  CAS  Google Scholar 

  133. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 503–507.

    PubMed  CAS  Google Scholar 

  134. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27–35.

    Article  PubMed  CAS  Google Scholar 

  135. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7: 1377–1381.

    PubMed  CAS  Google Scholar 

  136. Liu X-H, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56: 5125–5127.

    PubMed  CAS  Google Scholar 

  137. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985; 45: 1803–1808.

    PubMed  CAS  Google Scholar 

  138. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998; 122: 165–175.

    Article  PubMed  CAS  Google Scholar 

  139. Matsunaga K, Yoshimi N, Yamada Y, Shimizu M, Kawabata K, Ozawa Y, et al. Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-Nnitrosourea-induced mammary carcinogenesis in rats. Jpn J Cancer Res 1998; 89: 496–501.

    Article  PubMed  CAS  Google Scholar 

  140. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101–2103.

    PubMed  CAS  Google Scholar 

  141. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247–1250.

    Article  CAS  Google Scholar 

  142. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–1327.

    PubMed  CAS  Google Scholar 

  143. Norrish AE, Jackson RT, McRae CU. Nonsteroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77: 511–515.

    Article  PubMed  CAS  Google Scholar 

  144. Chaudry AA, Wahle KWJ, McClinton S, Moffat LEF. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57: 176–180.

    Article  PubMed  CAS  Google Scholar 

  145. Rose P, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991; 18: 243–254.

    Article  PubMed  CAS  Google Scholar 

  146. Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids 1992; 27: 798–803.

    Article  PubMed  CAS  Google Scholar 

  147. Lim JTE, Piazza GA, Han EK-H, Delohery TM, Li H, Finn TS, et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999; 58: 1097–1107.

    Article  PubMed  CAS  Google Scholar 

  148. Viljoen TC, van Aswegen CH, du Plessis DJ. Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Oncology 1995; 52: 465–469.

    Article  PubMed  CAS  Google Scholar 

  149. Gupta S, Srivastava M, Ahmand N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73–78.

    Article  PubMed  CAS  Google Scholar 

  150. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyllo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111–1118.

    Article  PubMed  CAS  Google Scholar 

  151. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251–265.

    Article  PubMed  CAS  Google Scholar 

  152. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473–480.

    PubMed  CAS  Google Scholar 

  153. Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001; 166: 88 2886.

    Google Scholar 

  154. Yokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184–194.

    Article  Google Scholar 

  155. Slaughter DP, Southwick HW, Smejkal W. `Field cancerization’ in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953; 6: 963–968.

    Article  PubMed  CAS  Google Scholar 

  156. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF Jr, et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J 2000; 14: 1499–1507.

    Article  PubMed  CAS  Google Scholar 

  157. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997; 18: 795–799.

    Article  PubMed  CAS  Google Scholar 

  158. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991–994.

    PubMed  CAS  Google Scholar 

  159. Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, et al. Inhibition of cyclooxygenase-2 expression: an approach to preventing head and neck cancer. Ann NYAcad Sci 1999; 889: 62–71.

    Article  CAS  Google Scholar 

  160. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-l-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001; 61: 1451–1456.

    PubMed  CAS  Google Scholar 

  161. Hubbard WC, Alley MC, Gray GN, Green KC, McLemore TL, Boyd MR. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 1989; 49: 8266–8832.

    Google Scholar 

  162. McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988; 48: 3140–3147.

    PubMed  CAS  Google Scholar 

  163. Hubbard WC, Alley MC, McLemore TL, Boyd MR. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res 1988; 48: 4770–4775.

    PubMed  CAS  Google Scholar 

  164. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A Expression of cyclooxygenase2 in human lung carcinoma. Cancer Res 1998; 58: 4997–5001.

    PubMed  CAS  Google Scholar 

  165. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K-I, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761–3764.

    PubMed  CAS  Google Scholar 

  166. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cylcooxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999; 14: 412–418.

    Article  PubMed  CAS  Google Scholar 

  167. El-Bayoumy K, Iatropoulos M, Amin S, Hoffmann D, Wynder EL. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3pyridyl)-l-butanone: the impact of a high-fat diet. Cancer Res 1999; 59: 1400–1403.

    PubMed  CAS  Google Scholar 

  168. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20, 809–20, 812.

    Article  PubMed  CAS  Google Scholar 

  169. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumori-genesis in A/J mice. Carcinogenesis 1997; 18: 1001–1006.

    Article  PubMed  CAS  Google Scholar 

  170. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58: 5354–5360.

    PubMed  CAS  Google Scholar 

  171. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. Jlmmunol 2000; 164: 361–370.

    CAS  Google Scholar 

  172. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care.CA Cancer J Clin 2000; 50:241–268.

    Google Scholar 

  173. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. Ca Cancer J Clin 1999; 49:33–64.

    Google Scholar 

  174. DiGiuseppe JA, Yeo CJ, Hruban RH. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Adv Anat Pathol 1996; 3: 139–155.

    Article  Google Scholar 

  175. Hahn SA, Schutte M, Hogue AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor-suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–353.

    Article  PubMed  CAS  Google Scholar 

  176. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987–990.

    PubMed  CAS  Google Scholar 

  177. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5: 2018–2024.

    PubMed  CAS  Google Scholar 

  178. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000; 20: 2625–2631.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gary J. Kelloff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vernon E. Steele PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline C. Sigman PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Ohio State University College of Medicine and School of Public Health, Columbus, OH, USA

    Randall E. Harris MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kelloff, G.J., Steele, V.E., Sigman, C.C. (2003). Chemoprevention of Cancer by NSAIDs and Selective COX-2 Blockade. In: Harris, R.E. (eds) COX-2 Blockade in Cancer Prevention and Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-302-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-302-6_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-304-6

  • Online ISBN: 978-1-59259-302-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation